EcoDrugPlus

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSOKIG00005003983
Gene Symbol: PPP3CA
3 Cross references
228 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSOKIG00005012789
Gene Symbol: PTK2
3 Cross references
183 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSOKIG00005007332
Gene Symbol: PTK2
3 Cross references
184 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSOKIG00005020915
Gene Symbol: PTPN11
3 Cross references
245 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSOKIG00005014685
Gene Symbol: PTPRB
1 Cross references
197 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSOKIG00005044333
Gene Symbol: PTPRB
3 Cross references
186 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSOKIG00005044484
Gene Symbol: PTPRB
1 Cross references
186 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSOKIG00005046641
Gene Symbol: PTPRB
3 Cross references
197 Possible Orthologues:

Protein-Tyrosine Kinase 2-Beta-Like

Ensembl ID : ENSOKIG00005037944
Gene Symbol: LOC109883186
3 Cross references
190 Possible Orthologues:

Protein-Tyrosine Kinase 2-Beta-Like

Ensembl ID : ENSOKIG00005009356
Gene Symbol: LOC109879499
3 Cross references
190 Possible Orthologues:

Proteinase-Activated Receptor 1-Like

Ensembl ID : ENSOKIG00005032517
Gene Symbol: LOC109896021
3 Cross references
216 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Src

Ensembl ID : ENSOKIG00005037346
Gene Symbol: LOC109908261
3 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).